iCAD Inc is a United Statesâ€‘based company. The Company develops artificial intelligence solutions designed to support healthcare providers in the detection and diagnosis of cancer. The company focuses on providing clinically proven AI technologies that assist medical professionals in identifying cancer earlier, improving diagnostic accuracy, and enhancing workflow efficiency. Its solutions include platforms for cancer detection, breast density assessment, and risk evaluation, enabling clinicians to analyze medical images and support patient care decisions. The company leverages advanced data, clinical evidence, and AIâ€‘driven technologies to deliver tools that integrate into existing healthcare systems and assist in screening and diagnostic processes across global markets.

Employees

Sector

Advanced Medical Equipment & Technology

More about the company

21/07/25	ICAD, Inc.(NasdaqCM:ICAD) dropped from S&P TMI Index	CI
18/07/25	ICAD, Inc.(NasdaqCM:ICAD) dropped from Russell Microcap Value Benchmark Index	CI

Market Cap	106M 92.27M 85.35M 79.66M 150M 9.98B 151M 1.01B 395M 4.91B 396M 388M 17.04B	P/E 2023	-9.35x	P/E 2024	-8.59x
Enterprise Value	88.75M 77.55M 71.73M 66.95M 126M 8.39B 127M 852M 332M 4.12B 333M 326M 14.32B	EV / Sales 2023	1.47x	EV / Sales 2024	1.6x
Free-Float	99.32%	Yield 2023 *	-	Yield 2024	-

21/07/25	ICAD, Inc.(NasdaqCM:ICAD) dropped from S&P TMI Index	CI
18/07/25	ICAD, Inc.(NasdaqCM:ICAD) dropped from Russell Microcap Value Benchmark Index	CI
18/07/25	ICAD, Inc.(NasdaqCM:ICAD) dropped from Russell Microcap Growth Benchmark Index	CI
18/07/25	ICAD, Inc.(NasdaqCM:ICAD) dropped from Russell 3000E Value Benchmark	CI
18/07/25	ICAD, Inc.(NasdaqCM:ICAD) dropped from Russell 3000E Growth Benchmark	CI
18/07/25	ICAD, Inc.(NasdaqCM:ICAD) dropped from Russell Microcap Growth Index	CI
18/07/25	ICAD, Inc.(NasdaqCM:ICAD) dropped from Russell Microcap Index	CI
18/07/25	ICAD, Inc.(NasdaqCM:ICAD) dropped from Russell Microcap Value Index	CI
18/07/25	ICAD, Inc.(NasdaqCM:ICAD) dropped from Russell 3000E Value Index	CI
18/07/25	RadNet, Inc. completed the acquistion of iCAD, Inc..	CI
17/07/25	RadNet's DeepHealth Unit Closes iCAD Acquisition	MT
17/07/25	ICAD, Inc.(NasdaqCM:ICAD) dropped from NASDAQ Composite Index	CI
14/05/25	ICAD, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI

18/04/25	RadNet's iCAD Deal to Expand its Digital Health Services and Geographic Presence, Truist Says	MT
17/04/25	BTIG Research Downgrades iCAD to Neutral From Buy	MT
19/07/23	Lake Street Adjusts Price Target on icad to $5 From $2.50, Maintains Buy Rating	MT
13/04/23	JMP Securities Adjusts iCAD's Price Target to $4 From $7, Keeps Outperform Rating	MT
04/04/23	Oppenheimer Adjusts iCAD Price Target to $4 From $5, Maintains Outperform Rating	MT

08/07/25	ICAD Announces Proxy Advisory Firms ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Acquisition by RadNet, Inc.	AQ
04/06/25	ICAD INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iCAD, Inc. - ICAD	BU
14/05/25	ICAD Reports Financial Results for First Quarter Ended March 31, 2025	AQ
29/04/25	ICAD Collaborates with Microsoft to provide access to its Mammography Solutions in Microsoft’s Precision Imaging Network (PIN)	AQ
17/04/25	ICAD INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iCAD, Inc. - ICAD	BU

iCAD Inc Stock Nasdaq

Stocks

US44934S1078

Advanced Medical Equipment & Technology

Valuation: iCAD Inc

Latest news : iCAD Inc

Analysts' recommendations: iCAD Inc

Press Releases: iCAD Inc

News in other languages: iCAD Inc

Managers and Directors: iCAD Inc

Other Advanced Medical Equipment & Technology

Financials

Company Profile

14/03/23	LA PREMIÈRE ÉTAPE DE L’OPÉRATION CONSISTE EN LA CESSION PAR ICAD…
26/04/21	CAC 40 : Les valeurs à suivre à Paris et en Europe
26/04/21	Les valeurs à suivre à Paris et en Europe (actualisé)
18/10/19	ICAD : annonce l’installation de la solution ProFound AI™ 2D pour la mammographie et pour la tomosynthèse (DBT) 3D au Centre d’Imagerie Paris Nord Sarcelles
25/01/19	Dow Jones Industrial Average : Wall Street attendue en hausse malgré Intel et les doutes sur la croissance

Manager	Title	Age	Since
Dana Brown CEO	Chief Executive Officer	61	10/03/2023
Mark Stolper DFI	Director of Finance/CFO	54	17/07/2025
Dave Katz SEC	Corporate Secretary	-	17/07/2025

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
THERMO FISHER SCIENTIFIC, INC.	-0.13%	-2.05%	+16.62%	-12.17%	172B
INTUITIVE SURGICAL, INC.	-0.94%	-3.26%	-20.89%	+22.99%	143B
DANAHER CORPORATION	+0.58%	-1.61%	-9.27%	-24.62%	126B
BOSTON SCIENTIFIC CORPORATION	-2.12%	-5.20%	-56.24%	-18.87%	65.89B
EDWARDS LIFESCIENCES CORPORATION	-1.69%	-0.46%	+16.32%	-5.97%	49.45B
SIEMENS HEALTHINEERS AG	+0.79%	-1.32%	-25.37%	-31.90%	44.05B
AGILENT TECHNOLOGIES, INC.	-0.45%	-3.14%	+9.46%	+6.58%	35.72B
WATERS CORPORATION	+0.79%	+0.14%	+4.56%	+37.65%	35.18B
GE HEALTHCARE TECHNOLOGIES INC.	-1.54%	-6.36%	-14.93%	-24.40%	27.58B
Average	-0.52%	-2.49%	-8.86%	-5.63%	77.68B
Weighted average by Cap.	-0.43%	-2.43%	-7.46%	-5.69%

	2023	2024
Net sales	17.32M 15.13M 14M 13.06M 24.53M 1.64B 24.71M 166M 64.72M 805M 65.02M 63.61M 2.8B	19.61M 17.13M 15.85M 14.79M 27.77M 1.85B 27.97M 188M 73.28M 911M 73.62M 72.02M 3.16B
Net income	-4.85M -4.24M -3.92M -3.66M -6.86M -458M -6.91M -46.55M -18.11M -225M -18.2M -17.8M -782M	-5.62M -4.91M -4.54M -4.24M -7.95M -531M -8.01M -53.94M -20.99M -261M -21.09M -20.63M -906M
Net Debt	-21.21M -18.53M -17.14M -16M -30.04M -2B -30.26M -204M -79.26M -985M -79.63M -77.9M -3.42B	-16.84M -14.72M -13.61M -12.71M -23.85M -1.59B -24.03M -162M -62.95M -783M -63.24M -61.87M -2.72B

End-of-day quote Nasdaq Other stock markets
- ^USD	-